PrEP Apretude LA denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for prep apretude la are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Apretude (Long-Acting Cabotegravir) as "Experimental" — and How to Appeal

Apretude (cabotegravir extended-release injectable suspension) received FDA approval for HIV pre-exposure prophylaxis (PrEP) in December 2021. A denial classifying it as experimental or investigational is factually inconsistent with its regulatory status and is among the most challengeable denial types in the appeal process. Aetna's own clinical policy bulletins are periodically updated; if the reviewer applied an outdated policy that predates FDA approval, the denial should be reversed on that basis alone.

## Why This Denial Is Appealable

An "experimental" determination requires Aetna to demonstrate that the treatment lacks sufficient clinical evidence for the proposed use. For an FDA-approved drug used for its approved indication, that standard is very difficult for the insurer to sustain. The burden shifts to Aetna to justify why it is classifying a federally approved agent as experimental, and an independent external reviewer will apply that standard rigorously.

## Your Federal Appeal Rights

• ACA §2719 / ERISA §503 — Non-grandfathered commercial and employer-sponsored plans must provide full-and-fair internal appeal and independent external review.
• External review window — Typically approximately four months from the adverse determination date. Track this carefully.
• Expedited review — If delay creates a serious clinical risk (e.g., ongoing high-risk exposure), request expedited processing, which typically resolves within 72 hours.

## Concrete Appeal Steps

1. Obtain the denial letter and the specific clinical policy Aetna applied — Identify the policy bulletin number and effective date. Compare it to the FDA approval date for Apretude. 2. File a Level 1 internal appeal — Cite FDA approval status, the approved indication, and your prescriber's documentation that Apretude is being used within its approved indication. 3. Request a peer-to-peer review — Your prescriber can request a direct conversation with Aetna's medical director, which frequently resolves experimental denials before escalation. 4. File for independent external review if internal appeals fail — an independent reviewer is not bound by Aetna's internal classification.

## Documentation to Gather

• FDA approval reference for Apretude in the PrEP indication — publicly available from the FDA website; include the approval date and indication statement in your appeal.
• Aetna clinical policy bulletin for Apretude or long-acting injectable PrEP — obtain the version applied to your claim and note its effective date relative to FDA approval.
• Prescriber letter confirming the drug is being used for its FDA-approved indication and that your clinical situation meets the approved use criteria.
• HIV testing records and clinical history confirming HIV-negative status and documented PrEP candidacy.
• Applicable guideline organization reference — the prescriber letter may note that your case aligns with recommendations from the relevant infectious disease or public health guideline organization, without citing specific numbers.

## Criteria-Mapping Structure

List each criterion Aetna used to classify Apretude as experimental. For each, write one sentence demonstrating why it is not met — citing FDA approval status, the applicable policy date, or chart documentation. A reviewer who sees that every experimental criterion is rebutted with a verifiable fact will have little basis to uphold the denial.